"For patients in high-deductible health plans or who have cost sharing arrangements the increases will hit them." Find out if ...
Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) have been given an average rating of “Moderate Buy” ...
HC Wainwright reiterated their buy rating on shares of Collegium Pharmaceutical (NASDAQ:COLL – Free Report) in a research report report published on Friday,Benzinga reports. They currently have a $50.
In December 2024, the collegium met candidates for high court judgeships in Rajasthan, Allahabad and Bombay to assess their suitability for elevation It will be a working holiday for the top three ...
Hosted on MSN15d
Needham Upgrades Collegium Pharmaceutical (COLL)Fintel reports that on January 10, 2025, Needham upgraded their outlook for Collegium Pharmaceutical (NasdaqGS:COLL) from Hold to Buy. Analyst Price Forecast Suggests 29.26% Upside As of December ...
Collegium's 2025 guidance surpasses estimates with projected sales of $735-$750M and adjusted EBITDA of $435-$450M. Analyst highlights growth potential from Jornay PM and strong pain portfolio ...
In a report released today, Serge Belanger from Needham upgraded Collegium Pharmaceutical (COLL – Research Report) to a Buy, with a price ...
In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Collegium Pharmaceutical (COLL – Research Report), with ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback